Published in Nat Rev Cancer on March 03, 2017
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inflammation and cancer. Nature (2002) 53.78
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature (2008) 11.66
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell (2013) 9.55
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol (2006) 7.25
Cells of origin in cancer. Nature (2011) 6.85
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book (2014) 6.22
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature (1990) 5.63
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (1992) 5.50
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol (2015) 4.95
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (1992) 4.75
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 4.66
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Structural organization of the bcr gene and its role in the Ph' translocation. Nature (1985) 4.08
Chromothripsis from DNA damage in micronuclei. Nature (2015) 4.04
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature (2012) 3.92
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81
CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell (2014) 3.68
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science (2016) 3.45
The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest (2007) 3.39
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37
Signalling ballet in space and time. Nat Rev Mol Cell Biol (2010) 3.32
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer (2010) 3.27
EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell (2012) 3.19
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (2015) 3.12
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol (2007) 3.06
Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med (2016) 3.05
Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell (2011) 3.03
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 2.91
Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science (2014) 2.89
The microbiome and cancer. Nat Rev Cancer (2013) 2.86
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68
Fibroblast growth factors and their receptors in cancer. Biochem J (2011) 2.66
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell (2013) 2.64
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54